Intelligence Feed event · Policy · 2026-09-17

    Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways

    Question

    Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways

    Direct answer

    Industry data from DelveInsight indicates that the clinical pipeline for hypertension includes more than 110 active programs across over 100 pharmaceutical entities, with over 40 therapies advancing in late-stage development. Development efforts emphasize novel biological mechanisms, including RNA interference and CRAC channel inhibition, led by developers such as Alnylam Pharmaceuticals, GSK, and Roche.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-17
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways”, revision 1, evidence through 2026-09-17. https://marketontology.com/market-events/2026-09-17/over-40-late-stage-hypertension-trials-progress-across-rnai-and-novel-pathways-ac15b5

    POLICY
    Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
    Industry data from DelveInsight indicates that the clinical pipeline for hypertension includes more than 110 active programs across over 100 pharmaceutical entities, with over 40 therapies advancing in late-stage development. Development efforts emphasize novel biological mechanisms, including RNA interference and CRAC channel inhibition, led by developers such as Alnylam Pharmaceuticals, GSK, and Roche.
    GSKRHHBY
    Impact
    54
    SEP 17
    SIG
    80%
    GSKRHHBY
    Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
    Industry data from DelveInsight indicates that the clinical pipeline for hypertension includes more than 110 active programs across over 100 pharmaceutical entities, with over 40 therapies advancing in late-stage development. Development efforts emphasize novel biological mechanisms, including RNA interference and CRAC channel inhibition, led by developers such as Alnylam Pharmaceuticals, GSK, and Roche.
    → Late-stage clinical trial advancement in RNAi hypertension candidates alters commercial revenue expectations for major biopharma developers including GSK and ALNY.
    Impact
    Industry data from DelveInsight indicates that the clinical pipeline for hypertension includes more than 110 active programs across over 100 pharmaceutical entities, with over 40 therapies advancing in late-stage development. Development efforts emphasize novel biological mechanisms, including RNA interference and CRAC channel inhibition, led by developers such as Alnylam Pharmaceuticals, GSK, and Roche.
    Affected
    GSKRHHBY
    Transmission
    Late-stage clinical trial advancement in RNAi hypertension candidates alters commercial revenue expectations for major biopharma developers including GSK and ALNY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GSKpipeline optionality in late-stage cardiovascular drug commercializationWatch1-3mGSK is developing advanced-stage hypertension pipeline assets.
    RHHBYcardiovascular therapeutic pipeline expansion and clinical readoutsWatch1-3mRoche listed among key biopharma developers pursuing novel hypertension mechanisms.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month